UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE
Abstract Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-tra...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-023-03339-3 |
| _version_ | 1797453595457617920 |
|---|---|
| author | Alistair J. Roddick Alexa Wonnacott David Webb Angela Watt Michael A. Watson Natalie Staplin Alex Riding Eirini Lioudaki Apexa Kuverji Mohsen El Kossi Patrick Holmes Matt Holloway Donald Fraser Chris Carvalho James O. Burton Sunil Bhandari William G. Herrington Andrew H. Frankel |
| author_facet | Alistair J. Roddick Alexa Wonnacott David Webb Angela Watt Michael A. Watson Natalie Staplin Alex Riding Eirini Lioudaki Apexa Kuverji Mohsen El Kossi Patrick Holmes Matt Holloway Donald Fraser Chris Carvalho James O. Burton Sunil Bhandari William G. Herrington Andrew H. Frankel |
| author_sort | Alistair J. Roddick |
| collection | DOAJ |
| description | Abstract Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full “lay” summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals. |
| first_indexed | 2024-03-09T15:25:05Z |
| format | Article |
| id | doaj.art-2551b161032e4b6e81d9951e0b305ac9 |
| institution | Directory Open Access Journal |
| issn | 1471-2369 |
| language | English |
| last_indexed | 2024-03-09T15:25:05Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj.art-2551b161032e4b6e81d9951e0b305ac92023-11-26T12:35:12ZengBMCBMC Nephrology1471-23692023-10-0124111810.1186/s12882-023-03339-3UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATEAlistair J. Roddick0Alexa Wonnacott1David Webb2Angela Watt3Michael A. Watson4Natalie Staplin5Alex Riding6Eirini Lioudaki7Apexa Kuverji8Mohsen El Kossi9Patrick Holmes10Matt Holloway11Donald Fraser12Chris Carvalho13James O. Burton14Sunil Bhandari15William G. Herrington16Andrew H. Frankel17The Medical Research Council Population Health Research Unit at the University of OxfordWales Kidney Research Unit, Cardiff UniversityDiabetes Research Centre, College of Life Sciences, University of LeicesterUKKA Patient RepresentativeUKKA Patient RepresentativeThe Medical Research Council Population Health Research Unit at the University of OxfordRoyal Free London NHS Foundation TrustKings College Hospital NHS TrustJohn Walls Renal Unit, Glenfield HospitalDoncaster Royal InfirmaryPrimary Care Diabetes SocietyEast Kent Hospitals University NHS Foundation TrustWales Kidney Research Unit, Cardiff UniversityNorth East London Integrated Care BoardDepartment of Cardiovascular Sciences, University of LeicesterHull University Teaching Hospitals NHS Trust and Hull York Medical SchoolThe Medical Research Council Population Health Research Unit at the University of OxfordImperial College Healthcare NHS TrustAbstract Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full “lay” summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals.https://doi.org/10.1186/s12882-023-03339-3GuidelineChronic kidney diseaseAcute kidney injuryGliflozin |
| spellingShingle | Alistair J. Roddick Alexa Wonnacott David Webb Angela Watt Michael A. Watson Natalie Staplin Alex Riding Eirini Lioudaki Apexa Kuverji Mohsen El Kossi Patrick Holmes Matt Holloway Donald Fraser Chris Carvalho James O. Burton Sunil Bhandari William G. Herrington Andrew H. Frankel UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE BMC Nephrology Guideline Chronic kidney disease Acute kidney injury Gliflozin |
| title | UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE |
| title_full | UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE |
| title_fullStr | UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE |
| title_full_unstemmed | UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE |
| title_short | UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE |
| title_sort | uk kidney association clinical practice guideline sodium glucose co transporter 2 sglt 2 inhibition in adults with kidney disease 2023 update |
| topic | Guideline Chronic kidney disease Acute kidney injury Gliflozin |
| url | https://doi.org/10.1186/s12882-023-03339-3 |
| work_keys_str_mv | AT alistairjroddick ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT alexawonnacott ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT davidwebb ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT angelawatt ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT michaelawatson ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT nataliestaplin ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT alexriding ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT eirinilioudaki ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT apexakuverji ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT mohsenelkossi ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT patrickholmes ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT mattholloway ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT donaldfraser ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT chriscarvalho ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT jamesoburton ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT sunilbhandari ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT williamgherrington ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update AT andrewhfrankel ukkidneyassociationclinicalpracticeguidelinesodiumglucosecotransporter2sglt2inhibitioninadultswithkidneydisease2023update |